

R&D Postdoctoral Challenge

At AstraZeneca, we push the boundaries of science to deliver life-changing medicines. Our ambition is to discover transformative breakthroughs that hold a key to improving the lives of people with some of the world's most complex diseases.


Our pioneering R&D is focused on preventing, modifying, and hopefully in the future curing disease, to deliver innovative medicines for diseases where there is currently huge unmet need. Our R&D approach is evolving from symptom control to disease modification, focusing on earlier and smarter interventions that defy the natural course of disease. By reaching more patients earlier, we aim to slow disease progression and drive remission.

About the R&D Postdoctoral Challenge

The R&D Postdoctoral Challenge invites outstanding scientists to propose their own innovative ideas that could help transform the treatment of some of the world's most complex diseases. Shortlisted applicants will have the opportunity to pitch their research proposals to a world-leading judging panel with the possibility of being awarded a fully funded postdoctoral position at AstraZeneca.

Entry criteria:

- Open to final year MD and/or PhD students and Postdoctoral Researchers, within 5 years of receiving their advance postgraduate degree (MD and/or PhD) by 31 December 2022
- Candidates may be based anywhere in the world
- Submission of innovative research proposals focused around:
 - Enhancing our understanding of disease biology
 - Designing next generation therapeutics
 - Pioneering new approaches to drive success in the clinic
- Entries open on 17 March 2022 and close on 26 May 2022



Pitching to world-leading judging panel:

Shortlisted applicants will have the opportunity to pitch their research proposals to a world-leading judging panel consisting of AstraZeneca and external life science leaders in October 2022. Proposals will be critiqued based on scientific merit, and opportunity to create real impact for patients, society and healthcare systems.

- **Dr Asma Al Mannaei**, Director of Healthcare Quality and Exec Director of Research and Innovation in Abu Dhabi Department of Health, UAE
- **Prof David Goldstein**, Director of the Institute for Genomic Medicine at the Columbia University Medical Center, US
- **Professor Christopher Lowe**, Emeritus Professor of Biotechnology in the Department of Chemical Engineering and Biotechnology, and Director of the Institute of Biotechnology and Director of the Cambridge Academy of Therapeutic Sciences at the University of Cambridge, UK
- **Dr Jenni Nordborg**, National Life Sciences Coordinator, The Office for Life Sciences, Sweden


AstraZeneca:

- **Prof Sir Mene Pangalos**, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca
- **Dr Susan Galbraith**, Executive Vice President, Oncology R&D, AstraZeneca
- **Dr Sharon Barr**, Senior Vice President, Head of Research and Product Development at Alexion, AstraZeneca's Rare Disease group

Supporting the next generation of scientific talent:

- Successful applicants will be awarded a fully funded postdoctoral position at AstraZeneca from Q1 2023 to translate their ideas into meaningful benefit for patients
- Opportunity to conduct research at one of AstraZeneca's leading R&D facilities for two years (with an option to extend for a third year) to pursue and develop the creative research ideas proposed
- Will join the vibrant AstraZeneca research community with:
 - Access to novel tools and technologies, compounds, expertise and mentoring
 - Support for professional development including congress presentations and scientific publications
 - Ability to build the foundations of professional networks that could last a lifetime

Key timings:



Further details:

More information on the R&D Postdoctoral Challenge can be found at:

<https://openinnovation.astrazeneca.com/rd-postdoctoral-challenge.html>